<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="16990">Bilirubin</z:chebi> <z:chebi fb="15" ids="17659">UDP</z:chebi>-glucuronyl transferase (BGT), <z:chebi fb="0" ids="16990">bilirubin</z:chebi> <z:chebi fb="15" ids="17659">UDP</z:chebi>-glucosyl transferase (BGLT) and <z:chebi fb="0" ids="16990">bilirubin</z:chebi> <z:chebi fb="15" ids="17659">UDP</z:chebi>-xylosyl transferase (BXT) activities were measured in wedge-biopsied liver specimens obtained from patients with various <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver diseases</z:e>, and compared with those in controls with <z:mpath ids='MPATH_458'>normal</z:mpath> liver histology </plain></SENT>
<SENT sid="1" pm="."><plain>BGT was measured alone using needle biopsy liver specimens from the patients with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> (15 patients) </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0220991" disease_type="Disease or Syndrome" abbrv="">Rotor's syndrome</z:e> (one) and posthepatitic <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> (3) </plain></SENT>
<SENT sid="3" pm="."><plain>BGT was decreased to about 30% of controls in <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e>, but showed no change in posthepatitic <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> and <z:e sem="disease" ids="C0220991" disease_type="Disease or Syndrome" abbrv="">Rotor's syndrome</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>About 90% decrease in BGT, and BGLT and BXT were observed in <z:e sem="disease" ids="C0268311" disease_type="Disease or Syndrome" abbrv="">Crigler-Najjar syndrome type II</z:e> (3 patients) </plain></SENT>
<SENT sid="5" pm="."><plain>In patients with <z:hpo ids='HP_0001081'>cholelithiasis</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0012115'>hepatitis</z:hpo>, statistically significant changes of these three enzymes were not observed, except the statistically significant increase in BGT activity in <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0012115'>hepatitis</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Slight increases in BGT and BXT activities were observed in anicteric cases with <z:hpo ids='HP_0001081'>cholelithiasis</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>The ratio of BGT, BGLT and BXT activities in controls was 1:0.50:0.98 (expressed as "per mg protein") </plain></SENT>
<SENT sid="8" pm="."><plain>Slight differences existed between the ratios of BGT, BGLT and BXT in various <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver diseases</z:e>, and this may suggest the separate identities of BGLT and BXT from BGT </plain></SENT>
<SENT sid="9" pm="."><plain>Determination of <z:chebi fb="0" ids="16990">bilirubin</z:chebi>-conjugation is essential in the diagnosis of <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> and <z:e sem="disease" ids="C0268311" disease_type="Disease or Syndrome" abbrv="">Crigler-Najjar syndrome type II</z:e>, but shows no specific change in the other <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver diseases</z:e> </plain></SENT>
</text></document>